Search results for "Narcotic"

showing 10 items of 106 documents

The gamma(2)-MSH peptide mediates a central analgesic effect via a GABA-ergic mechanism that is independent from activation of melanocortin receptors.

2001

Using the latency for tail-flick after thermal stimulation we have assessed the effects of alpha-, gamma(1)- and gamma(2)-MSH on nociceptive threshold in the mice. Intracisternal injections of gamma(2)-MSH induced a distinct analgesia, while gamma(1)-MSH in the same doses gave only a minor analgesia. Intracisternal alpha-MSH instead gave a short-term hyperalgesia. The effect of gamma(2)-MSH was not blocked by any of the MC(4)/MC(3)receptor antagonist HS014, naloxone or by the prior intracisternal administrations of gamma(1)-MSH. However, the gamma(2)-MSH analgesic response was completely attenuated by treating animals with the GABA(A)antagonist bicuculline. The gamma(2)-MSH analgesic effect…

MaleNarcotic Antagonists(+)-NaloxonePharmacologyGABA Antagonistschemistry.chemical_compoundMiceEndocrinologyDrug Interactionsgamma-Aminobutyric AcidAnalgesicsMice Inbred BALB Cintegumentary systemMuscimolNaloxoneReceptors MelanocortinNociceptorsGeneral MedicineReceptor antagonistNeurologyHyperalgesiamedicine.symptomhormones hormone substitutes and hormone antagonistsmedicine.drugPain ThresholdTailendocrine systemmedicine.medical_specialtyanimal structuresmedicine.drug_classCatalepsyBicucullinePeptides CyclicCellular and Molecular Neurosciencegamma-MSHMelanocortin receptorInternal medicinemedicineAnimalsGABA ModulatorsGABA AgonistsCatalepsyDiazepamEthanolEndocrine and Autonomic SystemsAntagonistCentral Nervous System DepressantsBicucullinemedicine.diseaseEndocrinologyMuscimolchemistryReceptors Corticotropinalpha-MSHNeuropeptides
researchProduct

Effects of endotoxin on neurally-mediated gastric acid secretion in the rat.

1998

Abstract The effects of a peripheral administration of E. coli endotoxin on neurally-mediated gastric acid secretion and the role of endogenous opioids or PAF receptors in endotoxin effects have been evaluated in the continuously perfused stomach of the anaesthetized rat. Gastric acid secretion stimulated by distension (20 cm H2O) was reduced dose-dependently by single intravenous bolus injection of endotoxin (0.1–10 μg kg−1). Doses of 5 μg kg−1 induced a peak reduction of distension-stimulated acid output and significantly reduced the secretory response induced by an intravenous bolus of 2-deoxy-d-glucose (150 mg kg−1). This dose of endotoxin did not significantly modify mean systemic arte…

Malemedicine.medical_specialtymedicine.drug_classNarcotic AntagonistsPharmaceutical ScienceBlood PressureReceptors Cell Surface(+)-NaloxonePlatelet Membrane GlycoproteinsDistensionDeoxyglucoseReceptors G-Protein-CoupledGastric AcidOpioid receptorInternal medicinemedicineEscherichia coliAnimalsRats WistarEndogenous opioidPharmacologyDose-Response Relationship Drugbusiness.industryNaloxoneGastric distensionStomachAntagonistAzepinesTriazolesReceptor antagonistRatsEndotoxinsEndocrinologyOpioid PeptidesReceptors OpioidGastric acidFemalemedicine.symptombusinessPlatelet Aggregation InhibitorsThe Journal of pharmacy and pharmacology
researchProduct

Loss of spatial learning in a patient with topographical disorientation in new environments

2003

The case is described of a patient who, following cerebral hypoxia, developed severe difficulty in orienting himself in new environments in the context of a mild global amnesic syndrome. Some episodes he related suggested that his main difficulty was remembering the spatial/directional value of landmarks he recognised. A neuroradiological examination documented severe bilateral atrophy of the hippocampi associated with atrophic changes in the cerebral hemispheres, most marked in the dorsal regions. Neuropsychological and experimental evaluation showed a severe deficit of spatial learning with substantially preserved ability to learn verbal and visual-object information. He was also virtuall…

Magnetic Resonance Imaging; Maze Learning; Orientation; Amnesia Anterograde; Heroin; Hippocampus; Humans; Hypoxia Brain; Confusion; Narcotics; Parietal Lobe; Memory Disorders; Frontal Lobe; Temporal Lobe; Street Drugs; Adult; Neuropsychological Tests; MaleMaleNeuropsychological TestsHippocampusParietal LobeHypoxia BrainConfusionHypoxiamedicine.diagnostic_testNeuropsychologyBrainStreet DrugNeuropsychological testMagnetic Resonance ImagingTemporal LobeFrontal LobePsychiatry and Mental healthNarcoticNeuropsychological TestSettore MED/26 - Neurologiamedicine.symptomPsychologyHumanMemory DisorderCognitive psychologyPaperAdultNarcoticsStreet DrugsAmnesiaHippocampuAnterogradeOrientationmedicineHumansMemory disorderMaze LearningSensory cueSpatial analysisMemory DisordersSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaIllicit DrugsTopographical disorientationmedicine.diseaseAmnesia AnterogradeHeroinAdult; Amnesia Anterograde; Confusion; Frontal Lobe; Heroin; Hippocampus; Humans; Hypoxia Brain; Magnetic Resonance Imaging; Male; Maze Learning; Memory Disorders; Narcotics; Neuropsychological Tests; Orientation; Parietal Lobe; Street Drugs; Temporal LobeSpatial learningSurgeryNeurology (clinical)AmnesiaNeuroscience
researchProduct

Pharmacological Management of Cancer Pain in the Elderly

2007

Existing studies indicate a high prevalence rate and poor management of cancer pain in the elderly. Pain is often considered an expected concomitant of aging, and older patients are considered more sensitive to opioids. Despite the well known pharmacokinetic changes in the elderly, the complex network of factors involved in the opioid response make the evaluation of a single element, such as age, more difficult. Notwithstanding such difficulties, appropriate analgesic treatment is able to control cancer pain in the elderly in most cases. Skills necessary to optimise pain control in older cancer patients include the ability to objectively assess functional age (not necessarily related to chr…

medicine.medical_specialtybusiness.industryAnalgesicChronic painPainCancerAnalgesics Non-Narcoticmedicine.diseaseAnalgesics OpioidPharmacotherapyQuality of lifeOpioidChemotherapy AdjuvantNeoplasmsmedicinePhysical therapyHumansPharmacology (medical)Geriatrics and GerontologyIntensive care medicineAdverse effectbusinessCancer painAgedmedicine.drugDrugs & Aging
researchProduct

Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study

2022

Abstract Background The opioid antagonist extended-release naltrexone (XR-NTX) in the treatment of opioid use disorder (OUD) is effective in terms of safety, abstinence from opioid use and retention in treatment. However, it is unclear how patients experience and adjust to losing the possibility of achieving an opioid effect. This qualitative study is the first to explore how people with opioid dependence experience XR-NTX treatment, focusing on the process of treatment over time. Methods Using a purposive sampling strategy, semi-structured interviews were undertaken with 19 persons with opioid use disorder (15 men, four women, 22–55 years of age) participating in a clinical trial of XR-NTX…

AdultMaleNarcotic AntagonistsGeneral MedicineMiddle AgedOpioid-Related DisordersInjections IntramuscularNaltrexoneAnalgesics OpioidYoung AdultVDP::Medisinske Fag: 700::Helsefag: 800Delayed-Action PreparationsHumansFemale
researchProduct

Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features

2006

Abstract In transbuccal absorption a major limitation could be the low permeability of the mucosa which implies low drug bioavailability. The ability of naltrexone hydrochloride (NLX) to penetrate a resembling histologically human buccal mucosa was assessed and the occurrence of any histomorphological changes observed. We used reconstituted human oral (RHO) non-keratinised epithelium as mucosal section and a Transwell diffusion cells system as bicompartmental model. Buccal permeation was expressed in terms of drug flux ( J s ) and permeability coefficients ( K p ). Data were collected using both artificial and natural human saliva. The main finding was that RHO does not restrain NLX permeat…

Naltrexone HydrochlorideSalivaTissue FixationCell SurvivalNarcotic AntagonistsPharmaceutical SciencePharmacologySettore MED/08 - Anatomia PatologicaEpitheliumPermeabilityAbsorptionDiffusionExcipientsSettore MED/28 - Malattie OdontostomatologichemedicineHumansNaltrexone hydrochlorideNLXIontophoresiBuccal permeationTransbuccal absorptionParaffin EmbeddingIontophoresisChemistryNarcotic antagonistMouth MucosaAdministration BuccalGeneral MedicineBuccal administrationIontophoresisPermeationReconstituted human oral epithelium (RHO)Electric StimulationNaltrexoneEpitheliummedicine.anatomical_structurePenetration enhancersSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoData Interpretation StatisticalBiophysicsBiotechnology
researchProduct

Effects of DA D1 and D2 antagonists on the sensitisation to the motor effects of morphine in mice

2002

Abstract Acute morphine administration produces hyperactivity in mice and repeated treatment induces an enhancement of this effect. In this experiment, we study the sensitisation to the hyperactivity induced by intermittent morphine administration (40 mg/kg) and the effects of dopamine (DA) antagonists on this phenomenon. Animals received three injections, separated by 48 h, and after each injection, their activity was registered between 30 and 60 min. In Experiment 1, animals were divided into two groups, which received saline and morphine (S–S–M) or only morphine (M–M–M). In Experiment 2, animals were divided into 12 groups. Half, which was designed to study the effects of DA antagonists …

MaleNarcoticsMotor ActivityPharmacologyMicechemistry.chemical_compoundDopamineAnimalsMedicineNeurotransmitterBiological PsychiatrySensitizationPharmacologyRacloprideSCH-23390Morphinebusiness.industryReceptors Dopamine D1AntagonistDopamine D2 Receptor Antagonistsmedicine.anatomical_structurechemistryToxicityMorphineDopamine Antagonistsbusinessmedicine.drugProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Reinstatement of Morphine-Induced Conditioned Place Preference in Mice by Priming Injections

2004

To construct a model of relapse of drug abuse in mice, the induction, we evaluated the extinction and reinstatement of morphine-induced place preference. In Experiment 1, we examined the effects of morphine (0, 2, 3, 5, 10, 20 and 40 mg/kg) in the conditioned place preference (CPP) paradigm. Mice showed CPP with 5, 10, 20 and 40 mg/kg. In Experiment 2, we evaluated the effects of two different extinction procedures. After conditioning with 40 mg/kg of morphine, the mice underwent daily extinction sessions of 60 or 15 min of duration. CPP was extinguished after seven and nine sessions, respectively. In Experiment 3, we tested the reinstating effects of several priming doses of morphine. Mice…

MaleNarcoticsReinforcement SchedulePharmacologyArticleExtinction Psychologicallcsh:RC321-571MiceRewardmedicineAnimalslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryDose-Response Relationship DrugMorphineExtinction (psychology)Conditioned place preferenceDose–response relationshipNeurologyAnesthesiaMorphineConditioning OperantConditioningNeurology (clinical)PsychologyReinforcement PsychologyPriming (psychology)Injections Intraperitonealmedicine.drugNeural Plasticity
researchProduct

Effectiveness of Safety Warnings in Atypical Antipsychotic Drugs

2009

Studies conducted to obtain drug authorization are often of short duration and based on small sample sizes in selected populations. Policies on drug safety rely on the validity of the methods used to achieve rapid and effective communication of new information. No formal evaluation has ever been made of the Spanish communications system, although indirect data have raised questions about its effectiveness.To evaluate the impact of two safety warnings issued by the Spanish Drug Agency, and of a later prior authorization requirement involving the use of atypical antipsychotic drugs in the elderly.The study was based on a time-series analysis constructed with data corresponding to monthly invo…

Olanzapinemedicine.medical_specialtymedicine.drug_classAtypical antipsychoticToxicologyCommunications systemInterrupted Time Series AnalysisBenzodiazepinesmedicineHumansPharmacology (medical)ZiprasidoneAmisulpridePractice Patterns Physicians'Medical prescriptionPsychiatryAgedPharmacologyRisperidoneDose-Response Relationship DrugInformation Disseminationbusiness.industryRisperidonemedicine.diseaseOlanzapineSpainDrug and Narcotic ControlDementiaMedical emergencybusinessAntipsychotic Agentsmedicine.drugDrug Safety
researchProduct

Slow release oral morphine versus methadone for the treatment of opioid use disorder

2019

ObjectiveTo assess the efficacy of slow release oral morphine (SROM) as a treatment for opioid use disorder (OUD).DesignSystematic review and meta-analysis of randomised controlled trials (RCTs).Data sourcesThree electronic databases were searched through 1 May 2018: the Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE. We also searched the following electronic registers for ongoing trials: ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Current Controlled Trials and the EU Clinical Trials Register.Eligibility criteria for selecting studiesWe included RCTs of all durations, assessing the effect of SROM on measures of treatment retention, heroin use…

Narcoticsmedicine.medical_specialtyAddictionAdministration OralCraving1681substance use treatmentHeroin03 medical and health sciences0302 clinical medicineSlow release oral morphine (SROM)Internal medicineOpiate Substitution TreatmentHumansMedicine1506030212 general & internal medicine10. No inequalityAdverse effectRandomized Controlled Trials as TopicMorphinebusiness.industryResearchsubstance misuseopioid use disorderOpioid use disorderGeneral MedicineOpioid-Related Disordersmedicine.disease3. Good healthmeta-analysisClinical trialoral morphineOpioid use disorderReducing heroin useDelayed-Action PreparationsMeta-analysisRelative riskmedicine.symptombusinessMethadone030217 neurology & neurosurgerymedicine.drugMethadoneBMJ Open
researchProduct